Bristol Myers Squibb reports positive ACTION-1 results: stock after-hours at EUR 51.60
Published on 10/12/2026 at 22:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Bristol Myers Squibb reported positive interim ACTION-1 results on October 12, 2026.
- RYZ101 met the Phase 3 trial’s primary progression-free-survival endpoint.
- The stock was at EUR 51.60 after-hours at Lang & Schwarz at 10:28 p.m. CEST.
On October 12, 2026, Bristol Myers Squibb announced positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial for RYZ101, an investigational radiopharmaceutical developed by RayzeBio, a Bristol Myers Squibb company. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival. At 10:28 p.m. CEST, the stock was at EUR 51.60 after-hours at Lang & Schwarz on October 12, 2026.
Trading day
Lang & Schwarz showed a bid of EUR 51.49 and an ask of EUR 51.70 at the same timestamp. The S&P 500 closed at 7,822.50, down 0.01 percent on October 12, 2026, according to 24/7 Wall St. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
ACTION-1 trial milestone
ACTION-1 evaluates RYZ101 against investigator’s choice of standard care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors whose disease progressed after Lutetium-177-based therapy. Bristol Myers Squibb said the safety results were consistent with the known RYZ101 safety profile. The company plans to discuss the interim data with the U.S. Food and Drug Administration, while detailed results are expected at a future medical meeting, according to the company release.
Tomorrow
Tomorrow: Bristol Myers Squibb’s next scheduled event listed by its investor-relations site is the Q3 2026 results conference call on October 29, 2026, according to Bristol Myers Squibb Investor Relations.
Market context: Market report S&P 500.
